MedPath

Commons, Marty

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema

Phase 2
Terminated
Conditions
Diabetic Macular Edema
Interventions
Drug: Placebo
First Posted Date
2008-10-07
Last Posted Date
2012-03-06
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
39
Registration Number
NCT00768040
Locations
🇺🇸

Retinal Consultants of Arizona, Phoenix, Arizona, United States

🇺🇸

Elman Retina Group, Baltimore, Maryland, United States

🇺🇸

Vitreo-Retinal Associates, Grand Rapids, Michigan, United States

and more 8 locations

Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR)

Phase 3
Completed
Conditions
CHRONIC MYELOGENOUS LEUKEMIA
Interventions
First Posted Date
2008-09-26
Last Posted Date
2016-11-08
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
207
Registration Number
NCT00760877
Locations
🇪🇸

Novartis Investigative Site, Madrid, Spain

A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension

Phase 2
Completed
Conditions
Essential Hypertension
Interventions
Drug: LCI699-matching Placebo
Drug: Eplerenone-matching Placebo
First Posted Date
2008-09-25
Last Posted Date
2021-07-06
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
628
Registration Number
NCT00758524
Locations
🇺🇸

Novartis Pharmaceuticals, East Hanover, New Jersey, United States

A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases

Phase 1
Terminated
Conditions
Prostate Cancer
Bone Metastases
Interventions
First Posted Date
2008-09-23
Last Posted Date
2020-12-19
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
3
Registration Number
NCT00757757
Locations
🇺🇸

CTRC, San Antonio, Texas, United States

🇺🇸

NV Cancer Institute, Las Vegas, Nevada, United States

Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib

Phase 4
Completed
Conditions
Gastrointestinal Stromal Tumors
Interventions
First Posted Date
2008-09-22
Last Posted Date
2025-02-18
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
34
Registration Number
NCT00756509
Locations
🇮🇹

Novartis Investigative Site, Milano, MI, Italy

Effect of APL180 on Endothelial Function in Familial Hypercholesterolemia Patients

Phase 2
Withdrawn
Conditions
Familial Hypercholesterolemia
Interventions
Drug: Placebo
First Posted Date
2008-09-12
Last Posted Date
2016-09-23
Lead Sponsor
Novartis Pharmaceuticals
Registration Number
NCT00751608

Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg

Phase 3
Terminated
Conditions
Gastrointestinal Stromal Tumors
Interventions
First Posted Date
2008-09-11
Last Posted Date
2014-03-26
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
94
Registration Number
NCT00751036
Locations
🇻🇪

Novartis Investigative Site, Caracas, Distrito Capital, Venezuela

A Clinical Study to Evaluate the Safety, Tolerability and Activity of a New Phosphate Binder (SBR759) in Patients With Chronic Kidney Disease on Hemodialysis

Phase 1
Completed
Conditions
Chronic Kidney Disease
Interventions
First Posted Date
2008-09-10
Last Posted Date
2020-12-19
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
60
Registration Number
NCT00750295
Locations
🇺🇸

Novartis Investigator Site, Denver, Colorado, United States

Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia

Phase 3
Terminated
Conditions
Leukaemia, Lymphocytic, Chronic
Interventions
Drug: chlorambucil, tablets
First Posted Date
2008-09-08
Last Posted Date
2019-06-25
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
447
Registration Number
NCT00748189
Locations
🇬🇧

Novartis Investigative Site, Uxbridge, United Kingdom

Feasibility of Doctors' Rooms-based Infusion of Zoledronic Acid

Phase 4
Completed
Conditions
Osteoporosis
Interventions
First Posted Date
2008-09-03
Last Posted Date
2017-02-27
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
186
Registration Number
NCT00745485
Locations
🇦🇺

Novartis Investigative Site, Nedlands, Australia

© Copyright 2025. All Rights Reserved by MedPath